Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Not enough quarterly data
for a 1-year trend
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Positive debt with no FCF to service it
Below 8%, may not cover cost of capital
Sigyn Therapeutics (SIGY) quality: score, margins and returns
Sigyn Therapeutics (SIGY) scores 30/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100 and -48.0% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Sigyn Therapeutics (SIGY) a high-quality business?+
Sigyn Therapeutics scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -48.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Sigyn Therapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from SIGY's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Sigyn Therapeutics scores well and where it falls behind.
What is Sigyn Therapeutics's return on invested capital (ROIC)?+
Sigyn Therapeutics earns about -48.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to SIGY's margins and growth on this scorecard to judge durability.
SourceQuality score computed from the 10-Q filed 14 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with SIGY
Spot a number that looks wrong? Check it in SIGY's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SIGY
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.